Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will participate in a fireside chat during the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 11:20 AM ET in Miami, Florida.
2024年6月6日，宾夕法尼亚州韦恩市（GLOBE NEWSWIRE） - Aclaris Therapeutics，Inc.（纳斯达克：ACRS）是一家临床阶段的生物制药公司，专注于开发针对免疫炎症性疾病的新型药物候选品。今天宣布，Aclaris的代总裁兼首席执行官Neal Walker博士将于2024年6月11日星期二美国佛罗里达州迈阿密时间上午11:20参加高盛第45届全球医疗保健会议期间的座谈会。
A webcast of the fireside chat may be accessed through the "Events" page of the "Investors" section of Aclaris' website, www.aclaristx.com. The webcast will be archived for at least 30 days on the Aclaris website.
可以通过Aclaris网站“投资者”部分的“事件”页面访问座谈会的网络直播。www.aclaristx.comAclaris Therapeutics, Inc.是一家临床阶段的生物制药公司，开发的新型药物候选物能够应对免疫炎症性疾病患者在缺乏满意治疗方法的情况下的需求。公司拥有一个多阶段的药物候选物组合，由一个探索蛋白激酶调节的强大的研发引擎提供支持。详情请访问其网站。
About Aclaris Therapeutics, Inc.
关于Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
Aclaris Therapeutics, Inc.是一家临床阶段的生物制药公司，开发的新型药物候选物能够应对免疫炎症性疾病患者在缺乏满意治疗方法的情况下的需求。公司拥有一个多阶段的药物候选物组合，由一个探索蛋白激酶调节的强大的研发引擎提供支持。详情请访问其网站。www.aclaristx.com.
Aclaris Therapeutics Contact:
Aclaris Therapeutics 联系方式：
Source: Aclaris Therapeutics, Inc.
来源：aclairs therapeutics, Inc.